Candriam Luxembourg S.C.A. lifted its stake in Juno Therapeutics Inc (NASDAQ:JUNO) by 16.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 141,000 shares of the biopharmaceutical company’s stock after acquiring an additional 20,000 shares during the quarter. Candriam Luxembourg S.C.A. owned approximately 0.12% of Juno Therapeutics worth $6,445,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in JUNO. The Manufacturers Life Insurance Company increased its position in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the last quarter. Advisor Group Inc. increased its position in shares of Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares during the last quarter. QS Investors LLC bought a new position in Juno Therapeutics during the second quarter worth about $135,000. Bronfman E.L. Rothschild L.P. grew its holdings in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue bought a new position in Juno Therapeutics during the fourth quarter worth about $173,000. 68.90% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Robert Azelby sold 1,816 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $44.96, for a total transaction of $81,647.36. Following the completion of the sale, the executive vice president now owns 70,832 shares in the company, valued at $3,184,606.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $391,650.00. Following the sale, the chief financial officer now owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 473,031 shares of company stock valued at $27,031,205. Corporate insiders own 15.08% of the company’s stock.
A number of equities analysts recently commented on the company. Citigroup cut Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 17th. Needham & Company LLC cut Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Maxim Group reiterated a “buy” rating and set a $56.00 price target on shares of Juno Therapeutics in a report on Thursday, November 2nd. Wells Fargo & Co cut Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Finally, Wedbush cut Juno Therapeutics from an “outperform” rating to a “neutral” rating in a report on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $51.20.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) opened at $85.82 on Thursday. Juno Therapeutics Inc has a 1-year low of $19.62 and a 1-year high of $86.28. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/15/candriam-luxembourg-s-c-a-buys-20000-shares-of-juno-therapeutics-inc-juno.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.